Affiliation:
1. Department of Experimental Pharmacology, National Institute of Oncology, 1122 Budapest, Hungary
2. National Tumor Biology Laboratory, National Institute of Oncology, 1122 Budapest, Hungary
3. Department of Surgical and Molecular Pathology, National Institute of Oncology, 1122 Budapest, Hungary
4. KINETO Lab Ltd., 1037 Budapest, Hungary
Abstract
Malignant melanoma is challenging to treat, and metastatic cases need chemotherapy strategies. Targeted inhibition of commonly mutant BRAF V600E by inhibitors is efficient but eventually leads to resistance and progression in the vast majority of cases. Numerous studies investigated the mechanisms of resistance in melanoma cell lines, and an increasing number of in vivo or clinical data are accumulating. In most cases, bypassing BRAF and resulting reactivation of the MAPK signaling, as well as alternative PI3K-AKT signaling activation are reported. However, several unique changes were also shown. We developed and used a patient-derived tumor xenograft (PDTX) model to screen resistance evolution in mice in vivo, maintaining tumor heterogeneity. Our results showed no substantial activation of the canonical pathways; however, RNAseq and qPCR data revealed several altered genes, such as GPR39, CD27, SLC15A3, IFI27, PDGFA, and ABCB1. Surprisingly, p53 activity, leading to apoptotic cell death, was unchanged. The found biomarkers can confer resistance in a subset of melanoma patients via immune modulation, microenvironment changes, or drug elimination. Our resistance model can be further used in testing specific inhibitors that could be used in future drug development, and combination therapy testing that can overcome inhibitor resistance in melanoma.
Funder
National Research, Development and Innovation Office
Reference56 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021
2. Cancer Statistics, 2023;Siegel;CA Cancer J. Clin.,2023
3. (2023, April 25). Malignant Melanoma: Practice Essentials, Background, Etiology. Available online: https://emedicine.medscape.com/article/280245-overview.
4. Real-World Treatment Patterns and Clinical Outcomes in Advanced Cutaneous Melanoma Patients in France;Sassolas;J. Eur. Acad. Dermatol. Venereol.,2018
5. Vemurafenib;Flaherty;Nat. Rev. Drug Discov.,2011
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献